新西兰毛利人哮喘用药模式与住院出院趋势:缩小族群不公平
该研究基于新西兰2013年1月至2023年12月12岁以上人群的国家级哮喘吸入药物配药数据和哮喘住院出院数据,比较毛利人与非毛利人的相对变化,重点对比2023年7–12月与2019年7–12月。结果显示两组布地奈德/福莫特罗配药均大幅增加,毛利人哮喘住院出院率下降幅度更大,但毛利人住院率仍为非毛利人的两倍半。
要点
- 2019–2023年布地奈德/福莫特罗配药毛利人相对增加111%、非毛利人增加115%。
- 毛利人哮喘住院出院率由142.5降至97.3/10万,下降32%,大于非毛利人的23%。
- 尽管差距缩小,毛利人哮喘住院率仍为非毛利人的两倍半。
核心结论
- 布地奈德/福莫特罗维持和/或缓解方案的配药显著增加与哮喘住院减少在毛利人和非毛利人中均呈时间关联,毛利人住院下降幅度更大。
- 族群间健康不公平有所缩小,但毛利人哮喘住院率仍为非毛利人的两倍半。
研究设计与样本
- 研究为新西兰全国哮喘吸入药物配药数据与哮喘住院出院数据的回顾性分析,覆盖2013年1月至2023年12月、12岁以上人群。
- 计算毛利人与非毛利人配药及哮喘住院率的相对变化,比较2023年7–12月与4年前同期2019年7–12月。
主要发现
- 2019–2023年布地奈德/福莫特罗配药在毛利人中相对增加111%,非毛利人增加115%。
- 毛利人哮喘住院出院率从142.5降至97.3/10万,绝对差45.2/10万,下降32%。
- 非毛利人哮喘住院出院率从49.4降至37.9/10万,绝对差11.5/10万,下降23%。
- 毛利人哮喘住院率仍为非毛利人的两倍半。
临床怎么用
- 在毛利人中推广布地奈德/福莫特罗维持和/或缓解方案与哮喘住院减少呈时间关联,可作为缩小族群差异的参考。
- 尽管住院率下降,毛利人哮喘住院负担仍显著高于非毛利人,需持续关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: In Aotearoa New Zealand (NZ) widespread transition to budesonide/formoterol maintenance and/or reliever regimens in clinical practice is temporally associated with reduced rates of asthma hospitalization. It is unknown whether this association is observed in Māori, the indigenous population of NZ, who experience a disproportionate burden from asthma. We investigated patterns in asthma medication use and hospital admissions in Māori in NZ. METHODS: Review of NZ national dispensing data for asthma inhaler medications and asthma hospital discharge data from January 2013 to December 2023 in the 12+ age group, with calculation of the relative change in dispensed medication and asthma hospitalization rates for Māori and non-Māori. The most recent six-month period, July to December 2023, is compared with the corresponding six-month period 4 years earlier, July to December 2019. RESULTS: Budesonide/formoterol dispensing increased for both Māori and non-Māori for 2019-2023, with a relative 111% and 115% increase, respectively. Between the two periods, asthma hospital discharges reduced from 142.5 to 97.3 per 100,000, absolute difference 45.2 per 100,000, a 32% reduction for Māori; and 49.4-37.9 per 100,000, absolute difference 11.5 per 100,000; a 23% reduction for non-Māori. CONCLUSION: The temporal association between a marked increase in dispensing of budesonide/formoterol maintenance and/or reliever regimens and reduced asthma hospitalization was observed for Māori and non-Māori, with a greater reduction in asthma hospitalization for Māori. Despite this reduction in health inequities, asthma hospitalization rates are two and a half times greater for Māori compared to non-Māori.
引用
- Eathorne A, Noble J, Hatter L, et al. Reducing ethnic inequities: Patterns of asthma medication use and hospital discharges in Māori in Aotearoa New Zealand. Respirology. 2024. PMID: 39662517. doi:10.1111/resp.14865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。